HUMA - Humacyte Corp Analyst Consensus Forecast

Corporate company logo of Humacyte Inc (HUMA)

Humacyte, Inc. (HUMA) is implementing autonomous bioreactors for the automated growth of vessels to minimize human error. The company is developing bioengineered tissues, expanding their application in cardiology and dialysis to mitigate industry risks. This price chart reflects a consensus forecast of 1.64. Management is focused on the final stages of testing and the launch of industrial-scale production for its innovative medical developments.

HUMA Humacyte, Inc.: Analyst Consensus Forecast in the range 07/04/2022 - 11/11/2026

Analytical breakdowns for Humacyte Corp (HUMA)

- share price and consensus valuation forecast:
Price Performance Chart humacyte.com|HUMA - Consensus Target
- market capitalization statistics:
Market Capitalization Humacyte Corp|HUMA - Total Company Value
- balance sheet equity data:
Accounting Value per Share Humacyte|HUMA - Book Capitalization|Market Capitalization to Book Value Ratio humacyte.com|HUMA - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Humacyte, Inc.|HUMA - Long-Term Debt to Capital|Current Liabilities to Capital Humacyte Inc.|HUMA - Company Debts|Debts to Book Capitalization Ratio Humacyte Corp|HUMA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Humacyte|Immediate Liquidity humacyte.com
- business earnings and investment ratios data:
HUMA - Net Profit|Net Profit Forecast Humacyte, Inc.|HUMA - Price to Earnings Ratio|Forward P/E Multiple Humacyte Inc|HUMA - PEG Multiple|Enterprise Value to EBITDA Ratio Humacyte Corp|HUMA - Operating profit before deduction of amortization|Earnings per share for the last four quarters Humacyte|HUMA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months humacyte.com|HUMA - Earnings per share growth in current year|Expected net earnings per share growth next year Humacyte, Inc.
Fundamental company analysis:humacyte.com - HUMA
Finished products of Humacyte

Investors are assessing the potential of Humacyte, Inc. (HUMA) through the lens of diversifying bioengineered vessels across cardiology and dialysis, which minimizes industry-specific risks. This indicator calculates the weighted average fair value of the asset, establishing a price protection corridor against market manipulation and volatility. By analyzing the consensus target price, one can evaluate the resilience of fundamental valuations and determine the reliability of the current price trajectory.

Competitors of Humacyte, Inc.

NTRA (natera.com) - Fair Value Consensus|Sera Prognostics, Inc. - Consensus Target